192 related articles for article (PubMed ID: 32394075)
1. Personalized radiation dosimetry for PRRT-how many scans are really required?
Freedman N; Sandström M; Kuten J; Shtraus N; Ospovat I; Schlocker A; Even-Sapir E
EJNMMI Phys; 2020 May; 7(1):26. PubMed ID: 32394075
[TBL] [Abstract][Full Text] [Related]
2. Kidney dosimetry in 777 patients during
Sandström M; Freedman N; Fröss-Baron K; Kahn T; Sundin A
EJNMMI Phys; 2020 Dec; 7(1):73. PubMed ID: 33296054
[TBL] [Abstract][Full Text] [Related]
3. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized
Del Prete M; Arsenault F; Saighi N; Zhao W; Buteau FA; Celler A; Beauregard JM
EJNMMI Phys; 2018 Oct; 5(1):25. PubMed ID: 30318563
[TBL] [Abstract][Full Text] [Related]
4. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
5. Reducing the number of CTs performed to monitor personalized dosimetry during peptide receptor radionuclide therapy (PRRT).
Chicheportiche A; Artoul F; Schwartz A; Grozinsky-Glasberg S; Meirovitz A; Gross DJ; Godefroy J
EJNMMI Phys; 2018 Jun; 5(1):10. PubMed ID: 29916115
[TBL] [Abstract][Full Text] [Related]
6. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for
Peterson AB; Mirando DM; Dewaraja YK
EJNMMI Res; 2023 Jun; 13(1):57. PubMed ID: 37306783
[TBL] [Abstract][Full Text] [Related]
7. Accuracy and uncertainty analysis of reduced time point imaging effect on time-integrated activity for 177Lu-DOTATATE PRRT in clinical patients and realistic simulations.
Peterson AB; Mirando DM; Dewaraja YK
Res Sq; 2023 Apr; ():. PubMed ID: 37131738
[No Abstract] [Full Text] [Related]
8. Personalized dosimetry of
Carter LM; Ocampo Ramos JC; Kesner AL
Biomed Phys Eng Express; 2021 Aug; 7(5):. PubMed ID: 34271565
[No Abstract] [Full Text] [Related]
9. Dosimetry after peptide receptor radionuclide therapy: impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management.
Chicheportiche A; Ben-Haim S; Grozinsky-Glasberg S; Oleinikov K; Meirovitz A; Gross DJ; Godefroy J
EJNMMI Phys; 2020 Jan; 7(1):5. PubMed ID: 31975156
[TBL] [Abstract][Full Text] [Related]
10. Personalized
Del Prete M; Buteau FA; Beauregard JM
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1490-1500. PubMed ID: 28361189
[TBL] [Abstract][Full Text] [Related]
11. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
12. Dose Mapping After Endoradiotherapy with
Hänscheid H; Lapa C; Buck AK; Lassmann M; Werner RA
J Nucl Med; 2018 Jan; 59(1):75-81. PubMed ID: 28588150
[TBL] [Abstract][Full Text] [Related]
13. Effect of image registration on 3D absorbed dose calculations in
Grassi E; Fioroni F; Berenato S; Patterson N; Ferri V; Braglia L; Filice A; Versari A; Iori M; Spezi E
Phys Med; 2018 Jan; 45():177-185. PubMed ID: 29472084
[TBL] [Abstract][Full Text] [Related]
14. Simple model for estimation of absorbed dose by organs and tumors after PRRT from a single SPECT/CT study.
Chicheportiche A; Sason M; Godefroy J; Krausz Y; Zidan M; Oleinikov K; Meirovitz A; Gross DJ; Grozinsky-Glasberg S; Ben-Haim S
EJNMMI Phys; 2021 Aug; 8(1):63. PubMed ID: 34436698
[TBL] [Abstract][Full Text] [Related]
15. Impact of Single-Time-Point Estimates of
Chicheportiche A; Sason M; Zidan M; Godefroy J; Krausz Y; Gross DJ; Grozinsky-Glasberg S; Ben-Haim S
J Nucl Med; 2023 Oct; 64(10):1610-1616. PubMed ID: 37500259
[TBL] [Abstract][Full Text] [Related]
16. Peptide Receptor Radionuclide Therapy (PRRT) with
Jahn U; Ilan E; Sandström M; Lubberink M; Garske-Román U; Sundin A
Cancers (Basel); 2021 Feb; 13(5):. PubMed ID: 33668887
[TBL] [Abstract][Full Text] [Related]
17. Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours.
Sandström M; Ilan E; Karlberg A; Johansson S; Freedman N; Garske-Román U
EJNMMI Phys; 2015 Dec; 2(1):24. PubMed ID: 26501825
[TBL] [Abstract][Full Text] [Related]
18. Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume.
Svensson J; Hagmarker L; Magnander T; Wängberg B; Bernhardt P
EJNMMI Phys; 2016 Dec; 3(1):15. PubMed ID: 27491429
[TBL] [Abstract][Full Text] [Related]
19. Predictive power of the post-treatment scans after the initial or first two courses of [
Chicheportiche A; Grozinsky-Glasberg S; Gross DJ; Krausz Y; Salmon A; Meirovitz A; Freedman N; Godefroy J
EJNMMI Phys; 2018 Dec; 5(1):36. PubMed ID: 30535780
[TBL] [Abstract][Full Text] [Related]
20. Practical kidney dosimetry in peptide receptor radionuclide therapy using [
Staanum PF; Frellsen AF; Olesen ML; Iversen P; Arveschoug AK
EJNMMI Phys; 2021 Nov; 8(1):78. PubMed ID: 34773508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]